TruSpine Technologies Plc

Transaction in Own Shares • May 31, 2023

National Storage Mechanism | Additional information

RNS Number : 2136B

TruSpine Technologies PLC

31 May 2023

31 May 2023

TruSpine Technologies plc

("TruSpine" or the "Company")

Result of General Meeting

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that resolutions 1 - 7 of the Requisition Resolutions put to shareholders at the requisitioned General Meeting, proposed by the Named Shareholders, held today were defeated.

Resolution 8, relating to the re-convening of the adjourned 2022 Annual General Meeting, was passed.  It is the Company's intention to shortly re-convene the 2022 Annual General Meeting.

The results of the poll voting (which includes votes submitted by proxy) are detailed below and will be available shortly on the Company's website: http://truspine.org/

	Resolution	For	%	Against	%	Total	Withheld*
1.	Norman Alec Charles Lott be and is hereby removed from the office of director of the Company with immediate effect.	43,257,869	47.54%	47,731,826	52.46%	90,989,695	-
2.	Nikunj Kantilal Patel be and is hereby removed from the office of director of the Company with immediate effect.	25,932,069	28.50%	65,057,626	71.50%	90,989,695	-
3.	Annabel Martha Schild be and is hereby removed from the office of director of the Company with immediate effect.	27,498,122	30.22%	63,491,573	69.78%	90,989,695	-
4.	Laurence Richard Strauss be and is hereby removed from the office of director of the Company with immediate effect.	42,086,200	45.85%	49,703,494	54.15%	91,789,694	-
5.	Todd Michael Cramer, having indicated his willingness to act, be and is hereby appointed a director of the Company with immediate effect.	26,051,848	30.61%	59,050,608	69.39%	85,102,456	5,887,239
6.	Peter Houghton, having indicated his willingness to act, be and is hereby appointed a director of the Company with immediate effect.	26,035,182	30.59%	59,067,275	69.41%	85,102,457	5,887,238
7.	Anthony Swoboda, having indicated his willingness to act, be and is hereby appointed a director of the Company with immediate effect.	37,515,629	44.08%	47,586,828	55.92%	85,102,457	5,887,238
8.	The adjourned 2022 Annual General Meeting be re-convened as soon as reasonably practical.	44,630,331	52.51%	40,358,125	47.49%	84,988,456	6,001,239

Capitalised terms used in this announcement have the meanings given to them in the circular published on 5 May 2023, unless the context provides otherwise.

TruSpine CEO Laurence Strauss commented: "I am pleased to report that all but one of the resolutions tabled by certain shareholders for today's requisitioned General Meeting have been defeated. I hope that as a company we can now draw a line under this matter and move forward so that we can take the necessary steps to realise the potential of our unique product portfolio. I look forward to reporting our progress to shareholders in due course."

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc	Tel: +44 (0)20 7118 0852
Laurence Strauss, Chief Executive Officer
Cairn Financial Advisers LLP (AQSE Corporate Adviser)	Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker)	Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)	Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Novus Communications (PR and IR)	Tel: +44 (0)20 7448 9839
Alan Green / Jacqueline Briscoe	[email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXFLFEVERILVIV